Seven Fleet Capital Management LP Has $10.16 Million Holdings in Enliven Therapeutics, Inc. $ELVN

Seven Fleet Capital Management LP grew its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 159.4% during the first quarter, HoldingsChannel reports. The institutional investor owned 259,283 shares of the company’s stock after buying an additional 159,330 shares during the period. Enliven Therapeutics accounts for 3.2% of Seven Fleet Capital Management LP’s portfolio, making the stock its 3rd largest position. Seven Fleet Capital Management LP’s holdings in Enliven Therapeutics were worth $10,164,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. KBC Group NV bought a new position in Enliven Therapeutics in the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after buying an additional 3,490 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the sale, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director owned 41,884 shares in the company, valued at $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,036 shares of company stock worth $1,430,676 in the last quarter. 3.00% of the stock is owned by insiders.

Enliven Therapeutics Stock Up 1.6%

Enliven Therapeutics stock opened at $54.81 on Friday. The firm has a market cap of $3.34 billion, a P/E ratio of -32.82 and a beta of 0.24. The business has a fifty day moving average of $46.75 and a two-hundred day moving average of $38.48. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $55.82.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. Equities analysts expect that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Guggenheim assumed coverage on Enliven Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target for the company. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Finally, Mizuho increased their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.